212 related articles for article (PubMed ID: 37733071)
1. Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure.
Nishihara Y; Nishimori M; Sawa T; Uemura K; Nagai S; Todo S; Oota E; Odajima S; Takeuchi K; Ichikawa Y; Kintsu M; Yamauchi Y; Shiraki H; Yamashita K; Fukuda T; Hisamatsu E; Shimizu M; Hirata KI; Tanaka H
Heart Vessels; 2024 Feb; 39(2):95-104. PubMed ID: 37733071
[TBL] [Abstract][Full Text] [Related]
2. Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan.
Correale M; Mallardi A; Tricarico L; Mazzeo P; Ferraretti A; Diella C; Romano V; Merolla G; Iacoviello M; Di Biase M; Brunetti ND
Acta Cardiol; 2022 Jul; 77(5):416-421. PubMed ID: 34353236
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
[TBL] [Abstract][Full Text] [Related]
4. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
[TBL] [Abstract][Full Text] [Related]
5. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
[TBL] [Abstract][Full Text] [Related]
6. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
[TBL] [Abstract][Full Text] [Related]
7. Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management.
Chang HY; Chen KC; Fong MC; Feng AN; Fu HN; Huang KC; Chong E; Yin WH
J Cardiol; 2020 Mar; 75(3):233-241. PubMed ID: 31563433
[TBL] [Abstract][Full Text] [Related]
8. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.
Foà A; Vaduganathan M; Claggett BL; Pabon MA; Lu H; Pfeffer MA; Packer M; Vardeny O; Rouleau JL; Lefkowitz M; Mentz RJ; Jhund PS; Desai AS; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2024 May; 83(18):1731-1739. PubMed ID: 38537919
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
De Vecchis R; Paccone A; Di Maio M
Minerva Cardioangiol; 2019 Dec; 67(6):456-463. PubMed ID: 31625704
[TBL] [Abstract][Full Text] [Related]
10. Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril/Valsartan in Patients with Nonischemic Dilated Cardiomyopathy.
Kim HM; Kim KH; Park JS; Oh BH
Medicina (Kaunas); 2021 Apr; 57(5):. PubMed ID: 33922990
[No Abstract] [Full Text] [Related]
11. Sacubitril/valsartan effect on left ventricular remodeling: the case of a super-responder.
Monzo L; Lanzillo C; Tota C; Lino S; Fusco A; Minati M; Martino A; Calò L
Curr Med Res Opin; 2019 May; 35(sup3):3-6. PubMed ID: 30894032
[TBL] [Abstract][Full Text] [Related]
12. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL;
Circ Heart Fail; 2020 Nov; 13(11):e007829. PubMed ID: 33016100
[TBL] [Abstract][Full Text] [Related]
13. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
[TBL] [Abstract][Full Text] [Related]
14. Effect of sacubitril/valsartan on cardiac remodeling compared with other renin-angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples.
Carluccio E; Dini FL; Correale M; Dattilo G; Ciccarelli M; Vannuccini F; Sforna S; Pacileo G; Masarone D; Scelsi L; Ghio S; Tocchetti CG; Mercurio V; Brunetti ND; Nodari S; Ambrosio G; Palazzuoli A;
Clin Res Cardiol; 2024 Jun; 113(6):856-865. PubMed ID: 37733084
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
[TBL] [Abstract][Full Text] [Related]
16. Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry.
Lund LH; Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Kalus S; Ferber PC; Koch C; Maggioni AP;
Int J Cardiol; 2023 Jan; 370():279-286. PubMed ID: 36216094
[TBL] [Abstract][Full Text] [Related]
17. Early improvement of strain imaging parameters predicts long-term response to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: An observational prospective study.
Camilli M; Iannaccone G; Russo M; Meucci MC; Chiorazzo G; Natali R; Mango F; Bonanni A; Montone RA; Graziani F; Locorotondo G; Massetti M; Lanza GA; Aspromonte N; Crea F; Lombardo A
Int J Cardiol; 2023 Sep; 387():131110. PubMed ID: 37290664
[TBL] [Abstract][Full Text] [Related]
18. Insights into implementation of sacubitril/valsartan into clinical practice.
Martens P; Beliën H; Dupont M; Mullens W
ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
[TBL] [Abstract][Full Text] [Related]
19. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
20. Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients.
Öz TK; Abdelnabi M; Fiore C; Almaghraby A; Cihan D; Babazade N; Haseeb Raza Naqvi S; Omar B; Dağdeviren B
Minerva Cardiol Angiol; 2022 Aug; 70(4):431-438. PubMed ID: 34713680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
